187269-40-5
基本信息
Bimosiamose
[1,1'-Biphenyl]-3-acetic acid, 3',3'''-(1,6-hexanediyl)bis[6'-(α-D-mannopyranosyloxy)-
物理化学性质
| 熔点 | 115-117° |
| 沸点 | 1051.0±65.0 °C(Predicted) |
| 密度 | 1.417±0.06 g/cm3(Predicted) |
| 储存条件 | -20°C储存 |
| 溶解度 | DMSO:100.0(Max Conc. mg/mL);115.89(Max Conc. mM) 0.1 M NaOH:25.0(Max Conc. mg/mL);28.97(Max Conc. mM) |
| 酸度系数(pKa) | 3.95±0.10(Predicted) |
| 形态 | 结晶固体 |
| 颜色 | White to off-white |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H302-H315-H319-H335 |
| 防范说明 | P261-P280-P301+P312-P302+P352-P305+P351+P338 |
常见问题列表
IC50: 88 μM (E-selectin), 20 μM (P-selectin), 86 μM (L-selectin)
Bimosiamose (TBC-1269) operates by inhibiting neutrophil recruitment to the site of inflammation through blocking the initial rolling phase of recruitment. Bimosiamose (TBC-1269) inhibits cell recruitment and does not possess any cytotoxic effect on neutrophils.
Bimosiamose (TBC-1269; 25 mg/kg; intravenous injection; Sprague-Dawley rats) treatment shows a significant increase in survival. Best overall survival, 70%, is observed when TBC-1269 is administered 15 minutes before reperfusion, and also shows a marked decrease in liver enzyme levels at 6 hours after reperfusion. Neutrophil migration is also significantly ameliorated (81%). The histologic damage scores is also improved.
| Animal Model: | Sprague-Dawley rats (200-225g) with ischemia and reperfusion (I/R) |
| Dosage: | 25 mg/kg |
| Administration: | Intravenous injection |
| Result: | Showed a significant increase in survival compared with controls. |